Vanda Pharmaceuticals (VNDA) said in a filing Monday that the US Food and Drug Administration's planned review timelines of its new drug application for tradipitant, a motion sickness treatment, goes against the Food Drug and Cosmetic Act.
The regulator has set a target decision date of Dec. 30, which is 12 months after the application was submitted and six months later than the statutory deadline, the company added.
Vanda called the FDA "broken" and "unaccountable" for taking longer than expected to review the drug, despite two large clinical studies with 681 participants showing positive results. The trials showed that tradipitant significantly reduced motion-induced vomiting compared to a placebo, the company said.
Vanda Pharmaceuticals shares were 2% up in recent trading activity.
Price: 5.08, Change: +0.10, Percent Change: +2.01
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.